ANALYSIS: Drug Price Fights Still Have Shot After One Suit Axed

Drugmakers still have a chance to unravel the Biden administration’s drug price negotiation program despite a blow to one legal challenge.

A federal district court in Texas Feb. 12 dismissed a lawsuit brought by the National Infusion Center Association (NICA) and other industry groups for lack of jurisdiction. NICA’s claims revolved around Medicare reimbursement for providers, and that led to its downfall.

The eight other lawsuits winding their way through the courts don’t involve providers, so even if they hit a roadblock, it likely won’t be for the same reason.

Provider Reimbursement

The lawsuits challenge a provision of the Biden ...